Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.44 |
| ▸ | CTSL | P07711 | 6/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | CTSH | P09668 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GRN | P28799 | 1/20 | 0.38 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16171793 | 1.00 | CTSK (0.44) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL19361697 | 0.98 | CTSK (0.42) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL16171788 | 0.93 | CTSK (0.36) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL19361731 | 0.93 | CTSK (0.36) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL23844710 | 0.86 | CTSK (0.44) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL14537024 | 0.86 | CTSK (0.44) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL16327608 | 0.84 | CTSK (0.45) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL22133208 | 0.84 | CTSK (0.45) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL13957700 | 0.84 | GRN (0.49) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL13707910 | 0.82 | CTSK (0.44) | CTSKCTSLCTSBCTSHCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | CTSK 471/4885CTSL 466/4885CTSB 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.